Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely

Weiß, Günter

doi:10.1016/j.cmi.2022.11.028

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike similar studies in outpatient settings,[ 3 , 4 , 5 , 6 , 8 ] we did not find a significant risk reduction for severe COVID-19 in our population – possibly due to the low numbers of severe COVID cases encountered in the Omicron era. Increased immune protection in the population from vaccination, previous infection or a combination of both [ 25 ] could potentially contribute to the general reduction in severe COVID-19 during the Omicron era.…”

Section: Discussionmentioning

confidence: 99%

Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission

Wee

Tay

Chiew

et al. 2023

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission

Wee

Tay

Chiew

et al. 2023

Clinical Microbiology and Infection

View full text Add to dashboard Cite

“…Importantly, patients with vasculitis and after KT have hardly any detectable T-cell response to SARS-CoV-2-specific antigens although tests are often positive, which can be traced back to a high, unspecific background activity of T-cell activation. Vasculitis and KT patients are poorly protected from infection and severe disease, putting them at the front of the line for receiving immediate anti-viral treatment in case of infection [ 42 ].…”

Section: Discussionmentioning

confidence: 99%

Virus-Subtype-Specific Cellular and Humoral Immune Response to a COVID-19 mRNA Vaccine in Chronic Kidney Disease Patients and Renal Transplant Recipients

Knell,

Böhm,

Jäger

et al. 2023

Microorganisms

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) or immunosuppression are at increased risk of severe SARS-CoV-2 infection. The vaccination of CKD patients has resulted in lower antibody concentrations and possibly reduced protection. However, little information is available on how T-cell-mediated immune response is affected in those patients and how vaccine-induced immune responses can neutralise different SARS-CoV-2 variants. Herein, we studied virus-specific humoral and cellular immune responses after two doses of mRNA-1273 (Moderna) vaccine in 42 patients suffering from CKD, small vessel vasculitis (maintenance phase), or kidney transplant recipients (KT). Serum and PBMCs from baseline and at three months after vaccination were used to determine SARS-CoV-2 S1-specific antibodies, neutralisation titers against SARS-CoV-2 WT, B1.617.2 (delta), and BA.1 (omicron) variants as well as virus-specific T-cells via IFNγ ELISpot assays. We observed a significant increase in quantitative and neutralising antibody titers against SARS-CoV-2 and significantly increased T-cell responses to SARS-CoV-2 S1 antigen after vaccination only in the CKD patients. In patients with vasculitis, neither humoral nor cellular responses were detected. In KT recipients, antibodies and virus neutralisation against WT and delta, but not against omicron BA.1, was assured. Importantly, we found no specific SARS-CoV-2 T-cell response in vasculitis and KT subjects, although unspecific T-cell activation was evident in most patients even before vaccination. While pre-dialysis CKD patients appear to mount an effective immune response for in vitro neutralisation of SARS-CoV-2, KT and vasculitis patients under immunosuppressive therapy were insufficiently protected from SARS-CoV-2 two months after the second dose of an mRNA vaccine.

show abstract

Who should receive oral antiviral therapy for severe acute respiratory syndrome coronavirus 2 infection in the omicron era? Choose wisely

Cited by 2 publications

References 12 publications

Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission

Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission

Virus-Subtype-Specific Cellular and Humoral Immune Response to a COVID-19 mRNA Vaccine in Chronic Kidney Disease Patients and Renal Transplant Recipients

Contact Info

Product

Resources

About